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Piglet immunization with a spike subunit vaccine enhances
disease by porcine epidemic diarrhea virus
Jieshi Yu 1, Chithra Sreenivasan1, Tirth Uprety1, Rongyuan Gao2, Chen Huang1, Ella J. Lee2, Steven Lawson3, Julie Nelson3,
Jane Christopher-Hennings3, Radhey S. Kaushik 2, Eric Nelson3, Diego G. Diel4, Ben M. Hause3, Feng Li1 and Dan Wang 1 ✉
Immunization with an insect cell lysate/baculovirus mixture containing recombinant porcine epidemic diarrhea virus (PEDV) spike
protein induced high levels of neutralizing antibodies in both mice and piglets. However, immunization of piglets with this vaccine
resulted in enhancement of disease symptoms and virus replication in vaccine recipients exposed to PEDV challenge. Thus, these
observations demonstrate a previously unrecognized challenge of PEDV vaccine research, which has important implications for
coronavirus vaccine development.
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Porcine epidemic diarrhea virus (PEDV), an alphacoronavirus, was
ﬁrst identiﬁed in the U.S. in May 2013 from diseased pigs
experiencing explosive epidemics of diarrhea and vomiting1,2. The
virus rapidly spread to most swine-producing states, causing a loss
of ~7 million pigs3.
Here, we used the standard Bac-to-Bac Baculovirus expression
system to produce a recombinant vaccine containing the spike
protein of PEDV, designated hereafter Bac-PEDV-S. Similarly, we
generated recombinant baculoviruses expressing Ferritin, designated Bac-Ferritin that served as a control. SDS-PAGE with
Coomassie-staining and Western-blot assay involving anti-PEDV
spike protein antibody identiﬁed a predominant protein band in
infected Sf9 cells that migrated as expected for a full-length PEDV
spike protein (Fig. 1a–b). Bac-PEDV-S, Bac-Ferritin, inactivated
PEDV vaccines and PBS formulated with adjuvant MONTANIDE ISA
50-V2, which were then administered intramuscularly into four
groups of 7-week-old BALB/c mice, respectively.
Serum samples collected from mice two weeks after the second
vaccination were analyzed to determine the immunogenicity of
Bac-PEDV-S and designated controls. The standard ﬂuorescent
focus neutralization (FFN) assay4 was used to measure the titers of
virus-neutralizing antibodies in vaccinated animals. Bac-PEDV-S
vaccine elicited the mean FFN titer of about 130, which was
signiﬁcantly higher (p < 0.01) than that observed in the BacFerritin group (no FFN antibodies detected) (Fig. 1c). The
inactivated PEDV vaccine-elicited mean FFN titers of about 50.
There were no detectable FFN antibodies in the mock control
group (Fig. 1c).
Next, we examined the immunogenicity of the Bac-PEDV-S
vaccine in piglets. Analyses of vaccine-induced neutralizing
antibody titers in the pre-challenge sera of the vaccinated piglets
showed that Bac-PEDV-S vaccinated animals achieved signiﬁcantly
higher levels of virus-neutralizing antibodies when compared to
animals in the Bac-Ferritin group (p < 0.0001) (Fig. 1d). Speciﬁcally,
all seven pigs receiving the Bac-PEDV-S vaccine developed
moderate neutralizing antibody titers ranging from 40 to 160
with a mean FFN antibody titer of 110. Neither Bac-Ferritin nor
mock control elicited any positive virus-neutralizing antibodies in

vaccinated piglets. 2/8 animals in the whole-virus inactivated
group possessed positive neutralizing antibody titers (40 and 80
respectively) (Fig. 1d).
Despite stimulating high-titer neutralizing antibodies, the BacPEDV-S vaccine group exhibited more severe (p = 0.09) diarrhea in
the majority of vaccinated animals than the Bac-Ferritin group
during the observation period after the challenge. Speciﬁcally, 3/7
of the vaccinated animals developed moderate to severe diarrhea
as early as 2-day post-challenge (dpc) and two animals in this
group showed minimal to moderate diarrhea even at 7 dpc
(Figs. 2a, c). At 4 dpc, 6/7 vaccinated animals experienced varying
levels of diarrhea (diarrhea scores ≥ 1), while only 3/8 animals in
the Bac-Ferritin group experienced diarrhea (Fig. 2b). Despite one
animal showing diarrhea at 2 dpc in the Bac-Ferritin group (Fig.
2a), no animal showed diarrhea and disease at 7 dpc (Fig. 2c).
Moreover, measurements of relative viral loads in fecal samples by
RT-qPCR indicated that animals in the Bac-PEDV-S group shed
signiﬁcantly higher levels of the virus than those in the Bac-Ferritin
group (p < 0.05) (Fig. 2d).
We also employed a sample pooling/RT-qPCR testing strategy
to investigate the fecal virus shedding. The results indicated that
the Bac-PEDV-S vaccine enhanced viral shedding especially at 2
and 4 dpc, with elevated levels of fecal virus shedding (i.e., relative
viral loads: 2.47 × 103 and 6.29 × 103 TCID50/ml, respectively),
which was in contrast to relative viral loads (9.86 × 102 and
5.11 × 102 TCID50/ml) for the Bac-Ferritin group at these two timepoints, respectively (Fig. 2e). Notably, there was a signiﬁcantly
lower (p < 0.001) averaged body weight gain (i.e., ~125% of the
baseline weight prior to virus challenge) in Bac-PEDV-S vaccine
group compared to the Bac-Ferritin group (i.e., ~160% of the
baseline weight) during the 11-day observation period after virus
challenge (Fig. 2f). Note the unvaccinated and virus challenge
group involving four piglets showed characteristics including
diarrhea scores, relative fecal virus shedding, the gain of body
weight similar to those exhibited in Bac-Ferritin group (Fig. 2a–f).
Taken together, these data indicated that Bac-PEDV-S vaccination
resulted in a marked enhancement of virus replication and
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Fig. 1 Bac-PEDV-S induced neutralizing antibodies in vaccinated mice and piglets. a, b The expression of the PEDV S protein (indicated by
an arrowhead) was conﬁrmed by SDS-PAGE with coomassie blue staining and Western blotting analysis probed with anti-PEDV S monoclonal
antibody. Neutralizing antibodies in mice (c) and piglets (d) of different treatment groups were evaluated by FFN assay4. The meaning of error
bars and marked signs were described in the “Methods” section.

exacerbation of clinical diarrhea and disease in immunized pigs
following homologous PEDV challenge.
To further analyze the associations between the neutralizing
antibody titers, viral shedding, and clinical signs, we plotted them
on individual levels (Fig. 2g–j). Speciﬁcally, 6/7 animals vaccinated
with the Bac-PEDV-S shed high levels of virus (>103 TCID50/ml)
and/or experienced diarrhea (diarrhea scores ≥ 1), in spite of the
presence of neutralizing antibodies (FFN titers ≥ 40). Nevertheless,
only 2/4 animals in the unvaccinated and challenge group, 4/8
animals in the Bac-Ferritin vaccine group and 3/7 animals in the
inactivated PEDV vaccine group showed relative viral shedding
titers higher than 103 TCID50/ml and/or experienced diarrhea
(diarrhea scores ≥ 1). In addition, 2/3 animals showing diarrhea
scores ≥ 1 and relative viral shedding titers ≥ 103 TCID50/ml in the
inactivated PEDV vaccine group also had FFN titers ≥ 40. Therefore, we concluded that the neutralizing antibody titers against
PEDV were not absolutely associated or shown to be a correlate of
protection as demonstrated in this study.
The mechanisms leading to the observed vaccine-induced
enhancement of PEDV replication and disease are unknown,
however, our observation appears to continue a theme of vaccinenpj Vaccines (2021) 22

related or antibody-dependent enhancement of infection demonstrated by previous studies, which includes the coronaviruses that
cause infectious peritonitis in felines or severe acute respiratory
syndrome in humans5–7. In light of the overall high levels of PEDVneutralizing antibody responses elicited by the Bac-PEDV-S
vaccine (Fig. 1c–d), it is possible that the observed enhancement
of the disease can be attributed to the PEDV spike-speciﬁc nonneutralizing antibody response. Considering that the immunogen
used in this study was a mixture of insect cell lysate and
baculovirus that expressed the PEDV spike proteins, our vaccine
preparation likely contained both pre-fusion and post-fusion
forms of the PEDV spike. Numerous studies on human coronaviruses including the Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have demonstrated that antibodies
targeting the pre-fusion form, not post-fusion form, of the spike
protein neutralize virus infection8–10. And therefore, we speculate
that non-neutralizing antibodies generated in piglets against the
post-fusion of PEDV spike protein present in our vaccine may play
an important role in the enhancement of clinical diarrhea and
virus replication observed in our study, which warrants further
Published in partnership with the Sealy Institute for Vaccine Sciences
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Fig. 2 Bac-PEDV-S vaccine group exhibited enhanced clinical symptoms and virus replication. a–c Fecal consistency was scored at
indicated time points for each group. d, e PEDV shedding in feces was tested by RT-qPCR and reported as the relative viral loads determined
by the standard curve. f The averaged body weight gain of piglets on indicated days post-challenge in each group was calculated by
comparison with body weight of animals on the day of the challenge. g–j The neutralizing antibody titers, relative viral loads, and diarrhea
scores were plotted together for individual piglets in different vaccination groups. The meaning of error bars and marked signs were
described in the “Methods” section.

investigation. Regardless of the mechanism, this study highlights a
previously unrecognized challenge in utilizing the baculovirusexpressed recombinant spike protein vaccine to control PEDV
infection of pigs, which has important implications for general
coronavirus vaccine development in humans and animals.

METHODS
Cells and viruses
Vero-76 cells (ATCC CRL-1587) were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) at 37 °C
with 5% CO2. The Spodoptera frugiperda Sf9 insect cells were purchased
from Thermo Fisher Scientiﬁc and cultured in the serum-free SF900 II
medium (Gibco) in suspension. The PEDV Colorado (PEDV-CO) strain
Published in partnership with the Sealy Institute for Vaccine Sciences

(GenBank: KF272920.1) obtained from the South Dakota Animal Disease
Research and Diagnostic Laboratory (ADRDL) was propagated in Vero cells.

Plasmid construction and recombinant baculovirus
production
The Ferritin gene and the coding sequence of a synthetic, codonoptimized full-length spike gene of PEDV-CO strain were cloned into the
pFHMSP-LIC-C vector (Addgene Catalog# 26100), respectively, which were
conducted by using an In-Fusion HD Cloning Kit (Clontech) according to
the manufacturer’s instructions. The resultant plasmids were then
transformed into DH10Bac E. coli cells (Thermo Fisher Scientiﬁc) carrying
a baculovirus shuttle vector (bacmid) and a helper plasmid to generate
recombinant bacmids. The colonies containing recombinant bacmids with
target genes were screened and further validated by PCR and DNA
sequencing. Puriﬁed recombinant bacmid DNAs were transfected into Sf9
npj Vaccines (2021) 22
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cells by Cellfectin™ II (Gibco) to generate recombinant baculoviruses, BacFerritin, and Bac-PEDV-S. The virus stocks with high titers were prepared
and used to produce the recombinant protein vaccine of interest.

SDS-PAGE and Western-blotting assay
Sf9 cells were infected with recombinant baculoviruses at a multiplicity of
infection (MOI) of 2. The supernatants were collected, and the cells were
lysed. The expression of the PEDV S protein was conﬁrmed by SDS-PAGE
with coomassie blue staining and Western-blotting using anti-PEDV S
monoclonal antibody (ADRDL). All blots or gels derived from the same
experiment and were processed in parallel.

Preparation of the recombinant spike protein and the wholevirus inactivated vaccines
The recombinant baculovirus vaccines, Bac-PEDV-S and Bac-Ferritin were
prepared by infecting Sf9 cells (1–2 × 106 cells/ml) with the recombinant
baculoviruses (at least 1 MOI). At 72–96 h post-infection, 200 ml of infected
cells were collected, and the supernatants containing viruses were further
concentrated around 100 times by ultracentrifugation at 24,000 rpm for 2 h
at 4 °C. The cell pellets were then resuspended by using the concentrated
supernatants to make the ﬁnal volume of about 10 ml. The mixtures were
mixed 1:1 (volume per volume, v/v) with adjuvant MONTANIDE ISA 50-V2
(SEPPIC, NJ, USA) to form Bac-PEDV-S and Bac-Ferritin vaccines. Inclusion of
the Bac-Ferritin encoding an irrelevant protein to PEDV in this study,
prepared under an identical condition, would serve as a control to rule out
possible non-speciﬁc protective effects derived from baculovirus culture
implicated in vaccine efﬁcacy. The whole-virus inactivated vaccine was
prepared via the treatment of the PEDV-CO virus (5 × 105 TCID50/ml) with
0.02% Beta-propiolactone (BPL) for 20 h at 4 °C. Following the virus
replication assay showing no detectable live viruses, the inactivated PEDVCO was mixed with the above adjuvant to formulate the inactivated
vaccine.

FFN assay
Virus neutralization antibody responses in immunized pigs were measured
by using the FFN assay established and performed by the South Dakota
ADRDL4. This method has been extensively used in the ﬁeld. Heat
inactivated serum samples were two-fold serially diluted in MEM
supplemented with 1.5 μg/ml TPCK-treated trypsin and then incubated
with 100 foci forming units/100 μl of cell culture adapted PEDV-CO stock at
37 °C for 1 h. After 1 h, the virus-serum mixture was added to Vero cell
monolayers and incubated at 37 °C for 2 h, followed by washing with MEM
supplemented with 1.5 μg/ml TPCK-treated trypsin. The plates were again
incubated for an additional 20–24 h and then ﬁxed with 80% acetone,
followed by staining with FITC conjugated mAb against PEDV nucleoprotein (NP) to visualize the infected cells. The highest dilution of the sera
showing ≥90% reduction in ﬂuorescent foci compared to negative controls
will be the endpoint neutralization titer. Serum samples with a FFN titer
<40 were scored negative.

Assessment of the immunogenicity of the Bac-PEDV-S vaccine
in mice
Twenty-four, 6-week-old female BALB/c mice (Jackson Laboratories) were
randomly divided into four groups. The mice were given one-week
acclimatization before vaccinating with 200 µl of adjuvanted Bac-Ferritin,
Bac-PEDV-S, and inactivated PEDV vaccines by intramuscular (IM) route,
respectively. The mock group was vaccinated IM with 200 µl of PBS.
Booster vaccination with the same dose was administered IM to all groups
at 14 days post-vaccination (dpv). Peripheral blood samples were collected
from the facial vein at 0 and 14 dpv to evaluate the serum antibody titers.
At 28 dpv, all the animals were euthanized by CO2 inhalation and blood
collected. The immune efﬁcacy of the vaccines was evaluated by
estimating the neutralization antibody titers in the sera by FFN assay as
described previously4. The mice study was approved by the Institutional
Animal Care and Use Committee (IACUC) of SDSU (IACUC approval no. 18052A). The authors have complied with all relevant ethical regulations for
animal testing and research.
npj Vaccines (2021) 22

Evaluation of the protective efﬁcacy of Bac-PEDV-S vaccine
piglets against PEDV challenge
We examined the immunogenicity and protective efﬁcacy of the recombinant Bac-PEDV-S vaccine in pigs. Control groups in this study included BacFerritin, inactivated PEDV, and mock immunization (PBS) groups (with and
without virus challenge). This study was approved by the IACUC of SDSU
(IACUC approval no. 18-057A). The participants have complied with all
relevant ethical regulations for animal testing and research. Neonatal piglets
farrowed from PEDV seronegative sows were acquired from Midwest
Research Swine. Blood samples were collected from the piglets to conﬁrm
the seronegative status before vaccination. The immunogenicity and
protective efﬁcacy of 2 ml of Bac-PEDV-S (n = 7) and inactivated PEDV (n
= 8) vaccines, were compared to the Bac-Ferritin (n = 8) and mock (n = 8)
groups. All the piglets were vaccinated with two doses at two-weeks intervals
intramuscularly. At 5 weeks of age, the piglets in all vaccination groups as
well as in one of the mock immunization (PBS) groups were challenged orally
with 2 ml of 2 × 105 TCID50/ml of PEDV-CO viruses. The animals were
monitored post-infection for clinical symptoms such as diarrhea, vomiting,
anorexia, body weight loss, and lethargy. Fecal consistency scoring, body
weight measurement, and rectal swab collection were conducted on days 0,
2, 4, 7, and 10 post-challenge (dpc). All the animals were euthanized on
10 dpc. The protective efﬁcacy of the vaccine was evaluated by estimating
the neutralization antibody titers in the sera by FFN4.

RT-qPCR analysis of virus RNA in fecal samples
Fecal samples, collected from piglets on 0, 2, 4, 7, and 10 dpc, were pooled
together from each group at the indicated time points. The samples collected
from piglets on 4 dpc were also tested individually. To make a standard curve,
the PEDV-CO virus (3.548 × 105 TCID50/ml) was prepared by 10-fold serial
dilutions from 101 to 106. Viral RNAs were extracted from these samples and
diluted virus standard samples using the MagMAX Viral RNA/DNA Isolation Kit
(Life Technologies, Carlsbad, CA). ADRDL performed RT-qPCR assays for these
samples according to the manufacturer’s instructions (EZ-PED/TGE/PDCoV
MPX 1.0, Tetracore, Rockville, MD). The relative viral loads in feces were
determined by plotting their Ct values in the contact of the standard curve.
The cut-off Ct value of the RT-qPCR was 38.

Statistical analysis
The number of animals per group used here is based on the power analysis of
the previous results with our vaccine study, which reached statistical power
>0.8 at a p-value of 0.05. Signiﬁcant differences in the means of anti-PEDV FFN
titers between the Bac-Ferritin and Bac-PEDV-S groups were determined by
the student t-tests in GraphPad Prism 8.0. The signiﬁcant differences in
diarrhea scores, relative viral loads, and percentage of body weight change
between different groups were determined by the one-way ANOVA and
Dunnett’s multiple comparisons test in GraphPad Prism 8.0. Values of p < 0.05
were considered signiﬁcant (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Values of p < 0.1 were also marked in ﬁgures. In Fig. 1, the dotted line
indicated the cutoff FFN antibody value (serum samples with FFN titer ≥ 40
counted as positive). An outlier (#) marked in Fig. 1c was not included in the
statistics test. In Fig. 2, dotted lines with a black arrowhead indicated the nondetectable level of PEDV in fecal samples; dotted lines at y-axis value across 40
indicated that a FFN titer ≥ 40 was counted as positive; dotted lines at x-axis
value across 3 indicated high levels of relative viral loads (103 TCID50/ml) in
fecal samples. Data (Figs. 1c–d, 2a–c, f) on the y-axis represent the mean
values ± SEM and error bars indicate SEM. Data (Fig. 2d) on the y-axis
represent the geometric mean with geometric standard deviation (SD) and
error bars indicate geometric SD.

Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.

DATA AVAILABILITY
The raw data used for the preparation of ﬁgures of this study are available from the
corresponding author upon reasonable request.
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